If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.


Home > News & events > News

6th September, 2022

NOVELTY scientific congress presence in 2022

Read More

21st July, 2022

NOVELTY treatable traits manuscript published

Read More

19th June, 2022

NOVELTY frequent productive cough manuscript published

Read More

7th May, 2022

NOVELTY mild asthma burden manuscript published

Now published in Respiratory Medicine: the burden of mild asthma in patients from the NOVELTY study.
Read More

6th July, 2021

Validation of the CAAT in NOVELTY ePoster Presented at ATS 2021

The validation of the Chronic Airways Assessment Test (CAAT) - ePoster presented at the ATS International Conference 2021.
Read More

30th March, 2021

NOVELTY baseline characteristics manuscript published

Now published in the European Respiratory Journal: baseline characteristics from the NOVELTY study, with accompanying video summary.
Read More

26th February, 2021

Respiratory Symptoms Questionnaire manuscript published

Now published in ERJ Open Research: validation of Respiratory Symptoms Questionnaire.
Read More

26th February, 2021

NOVELTY at ISPOR Europe 2020

The humanistic burden of mild asthma – ePoster presented at the virtual ISPOR Europe Conference 2020.
Read More

21st December, 2020


Six NOVELTY ePosters were presented at the virtual ERS Congress 2020, and the related abstracts have now been published online.
Read More

17th November, 2020

Observational studies review published

We are pleased to announce that ‘Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design’ has been published.
Read More

14th July, 2020


The COVID-19 pandemic is a key transformative event in the lifetime of the NOVELTY study ...
Read More

3rd June, 2020

The COVID-19 pandemic and NOVELTY

The COVID-19 pandemic is a key transformative event in the lifetime of the NOVELTY study. The NOVELTY study provides a unique opportunity to better understand the risk and outcomes of COVID-19 infection in patients with asthma and/or COPD.
Read More

18th March, 2020

An update on NOVELTY governance: the NOVELTY Scientific Community

The NOVELTY Scientific Community was established at the annual face-to-face meeting on 22 January 2020. This new structure represents an evolution in the NOVELTY scientific strategy, setting and delivery, bringing together the separate bodies of the Scientific Committee, the National Principal Investigators and the AstraZeneca science and evidence leads.
Read More

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study